Nvidia and Eli Lilly announced a $1 billion AI drug discovery lab today at the J.P. Morgan Healthcare Conference. The press releases are full of the expected language: "reinvent drug discovery," "accelerate medicine development," "foundation models for biology." Lilly's CEO David Ricks said they're "combining our volumes of data and scientific knowledge with Nvidia's computational power." But, MAN, there is a phrase in there that is doing an INSANE amount of hard word: Combining our volumes of data. How, exactly? The Missing Paragraph The coverage has something conspicuously absent: any discussion of how pharma data actually moves. The lab will be in South San Francisco. Lilly's clinical trial data, compound libraries, and patient information live in facilities scattered across Indiana, Ireland, and dozens of research sites worldwide. The announcement talks about "lab-in-the-loop" systems linking wet labs and dry labs in "24/7 AI-assisted experimentation." That's a lovely vision.…